• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Microsoft

Microsoft Built a Chat Bot to Match Patients to Clinical Trials

By
Bloomberg
Bloomberg
and
Dina Bass
Dina Bass
Down Arrow Button Icon
By
Bloomberg
Bloomberg
and
Dina Bass
Dina Bass
Down Arrow Button Icon
March 1, 2019, 8:31 AM ET

A chat bot that began as a hackathon project at Microsoft’s lab in Israel makes it easier for sick patients to find clinical trials that could provide otherwise unavailable medicines and therapies.

The Clinical Trials Bot lets patients and doctors search for studies related to a disease and then answer a succession of text questions. The bot then suggests links to trials that best match the patients’ needs. Drugmakers can also use it to find test subjects.

Microsoft won’t release the bot as its own product. Instead, the software giant is talking to pharmaceutical companies that it hopes will use the bot to find trial participants, while pitching it to other partners that could turn the technology into a tool for patients, said Hadas Bitran, group manager of Microsoft Healthcare Israel. Bitran declined to name possible partners because no deals have been agreed yet.

The project is part of a larger Microsoft (MSFT) health care bot initiative that’s helped partners build automatic chat programs for things like triaging patients and answering questions about insurance benefits. The clinical trials bot was accepted as part of the U.S. White House Presidential Innovation Fellows program and Bitran showed it on Thursday at a closed door event at the White House. She will demonstrate the tech publicly on Friday during a session at the U.S. Census Bureau.

Half of all clinical trials for new drugs and therapies never reach the number of patients needed to start, and many others are delayed for the same reason, Bitran said. Meanwhile patients, sometimes desperately sick, find it hard to comb through the roughly 50,000 trials worldwide and their arcane and lengthy criteria—typically 20 to 30 factors. Even doctors struggle to search quickly on behalf of patients, Bitran said.

“It was a big passion project for everyone involved,” Bitran said. “We heard stories of families who would sit for days and days looking at the trials.”

The technology uses a form of artificial intelligence called machine reading to ingest the selection criteria for each clinical trial. It uses this data to decide which questions to ask patients and how to match their answers to suitable trials.

Here’s how it works for patients: They type in a search, such as “trials for a 52-year old California female with breast cancer.” The bot responds with questions such as whether the patient had chemotherapy for metastatic disease—a cancer that has spread—and how far the patient can travel. It offers five choices that describe the patient’s current health and ability to be active and care for herself. As the patient selects from the multiple-choice answers, the software generates the next question and refines the list of available trials.

About the Authors
By Bloomberg
See full bioRight Arrow Button Icon
By Dina Bass
See full bioRight Arrow Button Icon

Latest in

Middle EastMilitary
Trump pledges retaliation after 3 Americans are killed in Syria attack that the U.S. blames on the Islamic State group
By Samar Kassabali, Bassem Mroue, Seung Min Kim and The Associated PressDecember 13, 2025
29 minutes ago
InvestingStock
There have been head fakes before, but this time may be different as the latest stock rotation out of AI is just getting started, analysts say
By Jason MaDecember 13, 2025
2 hours ago
Politicsdavid sacks
Can there be competency without conflict in Washington?
By Alyson ShontellDecember 13, 2025
3 hours ago
Investingspace
SpaceX sets $800 billion valuation, confirms 2026 IPO plans
By Loren Grush, Edward Ludlow and BloombergDecember 13, 2025
4 hours ago
PoliticsAffordable Care Act (ACA)
With just days to go before ACA subsidies expire, Congress is about to wrap up its work with no consensus solution in sight
By Kevin Freking, Lisa Mascaro and The Associated PressDecember 13, 2025
4 hours ago
PoliticsDonald Trump
Trump couldn’t insult his way to victory in Indiana redistricting battle. ‘Folks in our state don’t react well to being bullied’
By Thomas Beaumont, Isabella Volmert and The Associated PressDecember 13, 2025
4 hours ago

Most Popular

placeholder alt text
Economy
Tariffs are taxes and they were used to finance the federal government until the 1913 income tax. A top economist breaks it down
By Kent JonesDecember 12, 2025
1 day ago
placeholder alt text
Success
Apple cofounder Ronald Wayne sold his 10% stake for $800 in 1976—today it’d be worth up to $400 billion
By Preston ForeDecember 12, 2025
1 day ago
placeholder alt text
Success
40% of Stanford undergrads receive disability accommodations—but it’s become a college-wide phenomenon as Gen Z try to succeed in the current climate
By Preston ForeDecember 12, 2025
1 day ago
placeholder alt text
Economy
The Fed just ‘Trump-proofed’ itself with a unanimous move to preempt a potential leadership shake-up
By Jason MaDecember 12, 2025
23 hours ago
placeholder alt text
Economy
For the first time since Trump’s tariff rollout, import tax revenue has fallen, threatening his lofty plans to slash the $38 trillion national debt
By Sasha RogelbergDecember 12, 2025
1 day ago
placeholder alt text
Success
Apple CEO Tim Cook out-earns the average American’s salary in just 7 hours—to put that into context, he could buy a new $439,000 home in just 2 days
By Emma BurleighDecember 12, 2025
1 day ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.